MDRX, US01988P1084

Veradigm stock fell 2 percent as relisting plan takes shape

Published on 10/04/2026 at 20:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Veradigm stock was last at USD 4.90 on October 2, 2026, after a USD 0.10 daily decline. Its preliminary 2025 revenue range is USD 584-589 million.

MDRX, US01988P1084, Illustration mit AI erstellt.

Veradigm (ISIN US01988P1084) stock was last at USD 4.90 on the OTC Expert Market on October 2, 2026, down 2 percent from the previous close. The latest market move puts the healthcare technology company between its 52-week low of USD 3.00 and high of USD 6.00, while a September 15, 2026 filing outlined a strategy built around revenue recovery and a potential national-exchange relisting.

Revenue reset sets the tone

According to StockTitan, Veradigm presented preliminary unaudited 2025 revenue of USD 584 million to USD 589 million in its September 15, 2026 investor presentation. The 2025 range is below the companys estimated 2024 revenue range of USD 590 million to USD 595 million, representing a 1.0 percent midpoint decline.

The same presentation describes a reset, recover, reignite plan spanning provider, payer and life sciences operations. It also lists USD 120 million in cash and cash equivalents and USD 75 million in debt at year-end 2025, giving investors a direct balance-sheet frame for the restructuring effort.

Relisting depends on filings

The filing identifies Veradigm common stock as MDRX and the venue as N/A on the OTC Expert Market, according to the SEC. The company paired its relisting objective with a 2025 audit underway and a planned 2025 Form 10-K later in 2026, making filing progress a central operational checkpoint.

Veradigm also highlighted 2,300 associates, 1.7 billion patient visits and 148 million patient records. Those figures show the scale behind its provider, payer and life sciences model, but the lower 2025 revenue band keeps customer retention and execution at the center of the investment case.

Consensus points above market price

Investing.com lists a Buy consensus from 2 analysts, with 1 Buy, 1 Hold and 0 Sell ratings. The average 12-month price target is USD 6.50, with a USD 5.00 low and USD 8.00 high; the average target lies 32.7 percent above the USD 4.90 market price.

OTC price remains below yearly high

Veradigm stock was last at USD 4.90 on the OTC Expert Market on October 2, 2026, at 2:36 p.m. ET, with an intraday range of USD 4.75 to USD 5.14 and volume of 1,037 shares. Its market capitalization was USD 832.2 million on that date.